A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis

Rheumatology (Oxford). 2016 Oct;55(10):1871-9. doi: 10.1093/rheumatology/kew237. Epub 2016 Jun 21.

Abstract

Objective: Co-stimulatory T cell cytokines are important in the progression of RA. This study investigates the interplay between 4-1BB, a disintegrin and metalloprotease-17 (ADAM17) and galectin-9 (Gal-9) in RA.

Methods: Stimulated mononuclear cells from patients with chronic RA (n = 12) were co-incubated with tissue inhibitor of metalloproteinase, 4-1BB ligand and Gal-9. Plasma samples were examined for soluble 4-1BB (s4-1BB) in newly diagnosed, treatment-naïve patients with RA (n = 97). The 28-joint DAS with CRP (28DAS-CRP), total Sharp score, erosion score and joint space narrowing were used to evaluate treatment outcome serially over a 2-year period.

Results: RA CD4(+) and CD8(+) synovial T cells express high levels of 4-1BB. The addition of TNF-α to cultured synovial mononuclear cells increased shedding of 4-1BB. 4-1BB ligand only increased TNF-α shedding in combination with Gal-9. RNA interference-mediated knockdown of ADAM17 or the addition of an ADAM17 inhibitor reduced the 4-1BB shedding. Shedding of 4-1BB was not influenced by Gal-9. Plasma levels of s4-1BB were increased in early RA and correlated with the number of swollen joints at baseline. After 3 months of treatment, the plasma levels of s4-1BB were equal to those of the controls. Baseline plasma levels of s4-1BB were inversely correlated with DAS28-CRP after 2 years of treatment, but not with total Sharp score, erosion score or joint space narrowing.

Conclusion: ADAM17 induces 4-1BB shedding in RA. Gal-9 is pivotal for the function of 4-1BB and induction of TNF-α. Furthermore, high plasma levels of s4-1BB were associated with the number of swollen joints, but also with a low DAS28-CRP after 2 years treatment in early RA.

Keywords: 4-1BB; 4-1BBL; ADAM17; DAS28; TACE; TNF; galectin; outcome; rheumatoid arthritis; synovium.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • 4-1BB Ligand / metabolism
  • 4-1BB Ligand / physiology*
  • ADAM17 Protein / physiology*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / etiology*
  • Arthritis, Rheumatoid / immunology
  • Autoantibodies / immunology
  • CD8-Positive T-Lymphocytes / metabolism
  • Cells, Cultured
  • Disease Progression
  • Double-Blind Method
  • Enzyme-Linked Immunosorbent Assay
  • Galectins / physiology*
  • HEK293 Cells
  • Humans
  • Leukocytes, Mononuclear
  • Longitudinal Studies
  • Matrix Metalloproteinase 17 / physiology*
  • Methotrexate / therapeutic use
  • Synovial Fluid / chemistry
  • T-Lymphocytes / metabolism
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • 4-1BB Ligand
  • Antirheumatic Agents
  • Autoantibodies
  • Galectins
  • LGALS9 protein, human
  • Tumor Necrosis Factor-alpha
  • Matrix Metalloproteinase 17
  • ADAM17 Protein
  • Methotrexate